<?xml version="1.0"?>
<!DOCTYPE TimeML SYSTEM "TimeML.dtd">
<TimeML>
Ras Al Khaimah, United Arab Emirates -<TIMEX3 tid="t7" type="DATE" value="2017-01-29">Sunday, January 29th 2017</TIMEX3> [ ME NewsWire ] 
 
Upon expiration of his contract – which comes in Q2 <TIMEX3 tid="t2" type="DATE" value="2017">2017</TIMEX3> – Dr Ayman Sahli , Chief Executive Officer of Julphar , has decided not to renew. The Board respects his wishes and has accepted his decision. Processes are underway to select his successor. 
 
Commenting on Dr Ayman’s decision, His Highness Sheikh Faisal Bin Saqr Al Qasimi , Chairman of Julphar, said: "We appreciate Dr Ayman’s outstanding service for <TIMEX3 tid="t9" type="DURATION" value="P8Y" mod="MORE_THAN">more than eight years</TIMEX3>. Despite the challenging market conditions, Dr Ayman made a major contribution to Julphar and the company has achieved significant performance improvements and profitability under his leadership. On behalf of the Board, I sincerely wish him well for the future." 
 
"It has been a privilege to have had the opportunity to lead Julphar for <TIMEX3 tid="t10" type="DATE" value="200">the last decade</TIMEX3> and I am enormously proud of the accomplishments that have been made," said Dr Ayman Sahli. "The company has played such a positive role in my life. I am grateful for the support I have received from the Board of Directors and I express my heartfelt thanks to all employees for their dedication. I am confident that they will carry the company’s business forward to new heights." 
 
About Julphar 
 
Established in <TIMEX3 tid="t11" type="DATE" value="1980">1980</TIMEX3>, Julphar is the largest generic pharmaceutical manufacturer in Middle East and North Africa, producing over 200 branded products across its fifteen manufacturing facilities. Julphar’s mission is to offer high quality medicines at affordable prices, and its product portfolio includes: Wound, Anemia and Women Care, Adult Primary Care, Pediatric Primary Care, Gastro Care and Pain Management, Cardiopulmonary Care, and Consumer Care. In <TIMEX3 tid="t12" type="DATE" value="2012">2012</TIMEX3> Julphar launched Julphar Diabetes, a 150 million-dollar Active Pharmaceutical Ingredient (API) manufacturing facility that has the capacity to produce 1,500 kg of recombinant human insulin and insulin analogues crystals (rDNA). Julphar employs approximately 3,000 people around the world and registered sales revenue of AED 1.47 billion in the year ending <TIMEX3 tid="t13" type="DATE" value="2015">2015</TIMEX3>. For more information, please visit http://www.julphar.net . 
   Contacts 
Mehtap Teke 
 
Corporate Communication Manager 
 
M +971-55-<TIMEX3 tid="t14" type="DATE" value="1934-6-19">1934619</TIMEX3>, D +971-7-204-5209 
 
Tel +971-7-246-<TIMEX3 tid="t15" type="DATE" value="1461">1461</TIMEX3>, FAX +971-7-246-<TIMEX3 tid="t16" type="DATE" value="2462">2462</TIMEX3>,  mehtap.teke@julphar.net 
  
Permalink : http://www.me-newswire.net/news/3266/en
</TimeML>
